Metronomic chemotherapy and anti-angiogenesis: Can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?

APMIS

Volumn 122, Issue 7, 2014, Pages 565-579

  Norrby, Klas ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Angiogenesis assays; Autochthonous tumors; in vitro; in vivo; Inflammation; Metronomic chemotherapy; Reactive oxygen species

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; LACTOFERRIN; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS ASSAY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOCHTHONOUS TUMOR; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CELL SELECTION; CELL TYPE; CHICKEN; CLINICAL TRIAL (TOPIC); COLON POLYP; CULTURE MEDIUM; DRUG ADMINISTRATION ROUTE; ENDOTHELIUM CELL; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; METASTASIS; METRONOMIC CHEMOTHERAPY; MOUSE MODEL; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; TARGET CELL; TUMOR MODEL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS ASSAYS; AUTOCHTHONOUS TUMORS; IN VITRO; IN VIVO; INFLAMMATION; METRONOMIC CHEMOTHERAPY; REACTIVE OXYGEN SPECIES;

ADMINISTRATION, METRONOMIC; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; ARTIFACTS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; RATS; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME;

EID: 84902789168     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12201     Document Type: Review

References (106)

1. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1-15.
2. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16:1295-322.
3. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
4. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
5. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
6. Weiss SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17:1359-70.
7. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005;7:101-11.
8. Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452-9.
9. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250-9.
10. Hida K, Hida Y, Shindoh M. Understanding tumor cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008;99:459-66.
11. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev 2010;7:455-65.
12. Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010;468:824-8.
13. Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010;468:829-33.
14. McGuire TF, Sajithlal GB, Lu J, Nicholls RD, Prochownik EV. In vivo evolution of tumor-derived endothelial cells. PLoS ONE 2012;7:e37138, 1-11.
15. Sajithlal GB, McGuire TF, Lu J, Beer-Stolz D, Prochownik EV. Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer 2010;127:2268-78.
16. Deshane J, Chen S, Caballero S, Grochot-Przeczek A, Was H, Li Calzi S, et al. Stromal cell-derived factor 1 promotes angiogenesis via a hemen oxygenase 1-dependent mechanism. J Exp Med 2007;204:605-18.
17. Newman AC, Chou W, Welch-Reardon KM, Fong AH, Popson SA, Phan DT, et al. Analysis of stromal cell secretomes reveals a critical role of stromal cell-derived hepatocyte growth factor and fibronectin in angiogenesis. Arterioscl Thromb Vasc Biol 2013;33:513-22.
18. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. PNAS 2003;100:12917-22.
19. Hamano Y, Sugimoto H, Soubasakos MA, Kieran M, Olsen BR, Lawler J, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004;64:1570-4.
20. Damber JE, Vallbo C, Albertsson P, Lennernas B, Norrby K. The anti-tumor effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chem Pharmacol 2006;58:354-60.
21. Pasquier E, Kieran MW, Sterba J, Shaked Y, Baruchel S, Oberlin O, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol 2011;4:203-11.
22. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev 2004;4:423-36.
23. Dellapasqua S, Bertolini F, Banardi V, Campagnoli E, Scarano E, Torrisi R, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-905.
24. Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, Rabascio C, et al. Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 2009;15:7652-7.
25. Sikder H, Huso DL, Zhang H, Wang B, Ryu B, Hwang ST, et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003;4:291-9.
26. Emmenegger U, Kerbel RS. Five years of clinical experience with metronomic chemotherapy: achievements and perspectives. Onkologie 2007;30:606-8.
27. Reynolds AR. Potential relevance of Bell-shaped and U-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer. Dose-Response 2010;8:253-84.
28. Staton CA, Reed MWR, Brown NJ. A critical analysis of current in vitro and in vivo angiogenesis assays. Int J Exp Path 2009;90:195-221.
29. Albertsson P, Lennernas B, Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF-A. Acta Oncol 2006;45:144-55.
30. Albertsson P, Lennernas B, Norrby K. Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 2008;47:293-300.
31. Albertsson P, Lennernas B, Norrby K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol 2009;48:418-25.
32. Albertsson P, Lennernas B, Norrby K. Low-dose metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS 2012;120:147-56 (Open Access).
33. Norrby K, Nordenhem A. Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS 2010;118:949-57.
34. Albertsson P, Lennernas B, Norrby K. Chemotherapy and antiangiogenesis: drug-specific effects on microvessel sprouting. APMIS 2003;111:995-1003.
35. Lennernas B, Albertsson P, Lennernas H, Norrby K. Chemotherapy and antiangiogenesis: drug-specific, dose-related effects. Acta Oncol 2003;42:294-303.
36. Fioravanti A, Canu B, Ali G, Orlandi P, Allegrini G, Di Desidero T, et al. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol 2009;619:8-14.
37. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies. Arch Biochem Biophys 2008;476:107-12.
38. Finkel T, Holbrook N. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
39. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003;15:247-54.
40. Uy B, McGlashan SR, Shaikh SB. Measurement of reactive oxygen species in the culture media using Acridan Lumigen PS-3 assay. J Biomol Tech 2011;22:95-107.
41. Grzelak A, Rychlik B, Bartosz G. Reactive oxygen species are formed in cell media. Acta Biochim Pol 2000;47:1197-8.
42. Maguire A, Morrissey B, Walsh JE, Lyng FM. Medium-mediated effects increase cell killing in a human keratinocyte cell line exposed to solar-stimulated radiation. Int J Radiat Biol 2011;87:98-111.
43. 3 oxidation by vitamin C: cell culture studies. Biometals 2012;25:103-13.
44. Lewinska A, Wnuk M, Slota E, Bartosz G. Total anti-oxidant capacity of cell culture media. Clin Exp Pharmacol Physiol 2007;34:781-6.
45. Dröge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
46. Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, et al. Reactive oxygen intermediates increases vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996;98:1667-75.
47. Gerber H-P, McMurtrey A, Koalski J, Yan M, Keyt BA, Dixit V, et al. Vascular endothelial growth factor regulates endothelial cell survival through phosphatidylinositol 3′-kinase/Akt signal transduction pathway. J Biol Chem 1998;273:30336-43.
48. Colavitti R, Pani G, Bedogni B, Anzevino R, Borrello S, Waltenberger J, et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/kdr. J Biol Chem 2002;277:3101-8.
49. Maulik N, Das DK. Redox signaling in vascular angiogenesis. Free Rad Biol Med 2002;33:1047-60.
50. Patra CR, Kim J-H, Pramanik K, d'Uscio LV, Patra S, Pal K. Reactive oxygen species driven angiogenesis by inorganic nanorods. Nano Lett 2011;11:4932-8.
51. Li Y, Rory Goodwin C, Sang Y, Rosen EM, Laterra J, Xia S. Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. Anti Cancer Drugs 2009;20:770-8.
52. Yamada T, Egashira N, Imuta M, Yano T, Yamauchi Y, Watanabe H, et al. Role of oxidative stress in vinorelbine-induced vascular endothelial cell injury. Free Rad Biol Med 2010;48:120-7.
53. Liu F, Smith J, Zhang Z, Cole R, Herron BJ. Genetic heterogeneity of skin microvasculature. Dev Biol 2010;340:480-9.
54. Lau ATY, Wang Y, Chiu J-F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008;104:657-67.
55. Verbridge SS, Choi NW, Zheng Y, Brooks DJ, Stoock AD, Fischbach C. Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis. Tissue Eng Part A 2010;16:2133-41.
56. Yang M, Stapor PC, Peirce SM, Betancourt AM, Murfee WL. Rat mesentery exteriorization: a model for investigating the cellular dynamics involved in angiogenesis. J Vis Exp 2012;63:e3954 (Open Access).
57. Stapor PC, Azimi MS, Ahsan T, Murfee WL. An angiogenesis model for investigating multicellular interactions across intact microvascular networks. Am J Physiol Heart Circ Physiol 2013;304:H235-45.
58. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
59. Norrby K, Enerbäck L, Franzén L. Mast cell activation and tissue cell proliferation. Cell Tiss Res 1976;170:289-303.
60. Norrby K, Enestrom S. Cellular and extracellular changes following mast-cell secretion in avascular rat mesentery. An electron-microscopic study. Cell Tiss Res 1984;235:339-45.
61. Norrby K. Mast cells and angiogenesis. APMIS 2002;110:355-71.
62. Fainaru O, Adini A, Benny O, Adini I, Short S, Bazinet L, et al. Dendritic cells support angiogenesis and promote lesion growth in a murine model of endometriosis. FASEB J 2008;22:522-9.
63. Lin EY, Pollard JW. Tumor-associated macrophages press the switch in breast cancer. Cancer Res 2007;67:5064-6.
64. Sozzani S, Rusnati M, Riboldi E, Mitola S, Presta M. Dendritic cell-endothelial cross-talk in angiogenesis. Trends Immunol 2007;28:385-92.
65. Fainaru O, Almog N, Yung CW, Nakai K, Montoya-Zavala M, Abdollahi A, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J 2010;24:1411-8.
66. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
67. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007;13:1211-8.
68. Norrby K, Jakobsson A, Sörbo J. Mast-cell-mediated angiogenesis: a novel experimental model using the rat mesentery. Virchows Arch B Cell Pathol Incl Mol Pathol 1986;52:195-206.
69. Kinet J-P. The essential role of mast cells in orchestrating inflammation. Immunol Rev 2007;217:5-7.
70. Norrby K. In vivo models of angiogenesis. J Cell Mol Med 2006;10:588-612.
71. Yang Y, Zhang Y, Hong H, Liu G, Leigh BR, Cai W. In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Imaging 2011;38:2066-76.
72. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002;94:883-93.
73. Hendrix MJ, Seftor EA, Seftor RE, Kasemeier-Kulesa J, Kulesa PM, Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat Rev Cancer 2007;7:246-55.
74. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-61.
75. Combest AJ, Roberts PJ, Dillon PM, Sandison K, Hanna SK, Ross C, et al. Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors. Oncologist 2012;17:1303-16.
76. Rohan RM, Fernandez A, Udagawa T, Yuan J, D'Amato RJ. Genetic heterogeneity of angiogenesis in mice. FASEB J 2000;14:871-6.
77. Sampaio FP, Castro PR, Marques SM, Campos PP, Ferreira MA, Andrade SP. Genetic background determines inflammatory angiogenesis response to dipyridamole in mice. Exp Biol Med 2012;237:1084-92.
78. Marques SM, Campos PP, Castro PR, Cardoso CC, Ferreira MA, Andrade SP. Genetic background determines mouse strain differences in inflammatory angiogenesis. Microvasc Res 2011;82:246-52.
79. Italiano JE, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet (alpha) granules and differentially released. Blood 2008;111:1227-33.
80. Battinelli EM, Markens BA, Italiano JE. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011;118:1359-69.
81. Sabrkhany S, Griffioen AW, oude Egbrink MGA. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011;1815:189-96.
82. St. Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
83. Hasan J, Shnyder SD, Bibby M, Double JA, Bicknell R, Jayson GC. Quantitative angiogenesis assays in vivo-a review. Angiogenesis 2004;7:1-16.
84. Auerbach R. An Overview of Current Angiogenesis Assays: Choice of Assay, Precautions in Interpretation, Future Requirements and Directions. In: Staton CA, Lewis C, Bicknell R, editors. Angiogenesis Assays. Chichester: Wiley, 2006: 361-79.
85. Melero-Martin JM, Bischoff J. An in vivo experimental model for postnatal vasculogenesis. Meth Enzymol 2008;445:303-29.
86. Norrby KC. Rat mesentery angiogenesis assay. J Vis Exp 2011;52:e3078 (Open Access).
87. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF. Vascular permeability factor/vascular growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 1998;58:1278-84.
88. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992;1121:130-6.
89. Baker EN, Anderson BF, Baker HM, Haridas M, Jameson GB, Norris GE, et al. Structure, function and flexibility of human lactoferrin. Int J Biol Macromol 1991;13:122-9.
90. Cerven D, DeGeorge G, Bethell D. 28-day repeated dose oral toxicity of recombinant human apo-lactoferrin or recombinant human lysozyme in rats. Reg Tox Pharmacol 2008;51:162-7.
91. Tamano S, Sekine K, Takase M, Yamauchi K, Iigo M, Tsuda H. Lack of chronic oral toxicity of chemopreventive bovine lactoferrin in F344/DuCrj rats. Asian Pac J Cancer Prev 2008;9:313-6.
92. Norrby K, Mattsby-Baltzer I, Innocenti M, Tuneberg S. Orally administered bovine lactoferrin systemically inhibits VEGF165-mediated angiogenesis in the rat. Int J Cancer 2001;91:236-40.
93. Mader JS, Smyth D, Marshall J, Hoskin DW. Bovine lactoferricin inhibits fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am J Pathol 2006;169:1753-66.
94. Shimamura M, Yamamoto Y, Ashino H, Oikawa T, Hazato T, Tsuda H, et al. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int J Cancer 2004;111:111-6.
95. Sekine K, Watanabe E, Nakamura J, Takasuka N, Kim DJ, Asamoto M, et al. Inhibition of Azoxymethane-initiated colon tumour by bovine lactoferrin administration in F344 rats. Jpn J Cancer Res 1967;88:523-6.
96. Yoo YC, Watanabe S, Watanabe R, Hata K, Shimazaki K, Azuma I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn J Cancer Res 1997;88:184-90.
97. Tsuda H, Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T, et al. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 2010;23:399-409.
98. Tung YT, Chen HL, Yen CC, Lee PY, Tsai HC, Lin MF, et al. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. J Dairy Sci 2013;96:2095-106.
99. Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T, Saito D, et al. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res 2009;2:975-83.
100. Adini A, Fainaru O, Udagawa T, Connor KM, Folkman J, D'Amato RJ. Matrigel cytometry: a novel method for quantifying angiogenesis in vivo. J Immunol Methods 2009;342:78-81.
101. Auerbach R, Kubai L, Knighton D, Folkman J. A simple procedure for the long-term cultivation of chicken embryos. Dev Biol 1974;41:391-4.
102. Gimbrone MA, Cotran RS, Leapman SB, Folkman J. Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 1974;52:413-27.
103. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-28.
104. Anderson CR, Hastings NE, Blackman BR, Price RJ. Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling. Am J Pathol 2008;173:1220-8.
105. Mattsby-Baltzer I, Jakobsson A, Sorbo J, Norrby K. Endotoxin is angiogenic. Int J Exp Path 1994;75:191-6.
106. Ramanathan M, Pinhal-Enfield G, Hao I, Leibovich SJ. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 2007;18:14-23.